Patents Examined by Brian Hartnett
-
Patent number: 11629199Abstract: The present application relates to specific binding members that bind carbonic anhydrase IX (CAIX). In particular, the present application relates to the treatment, diagnosis and detection of tumours, e.g. solid tumours, using specific binding members that bind CAIX. The specific binding member may be conjugated to a biocidal or cytotoxic molecule, or to a detectable label.Type: GrantFiled: December 19, 2018Date of Patent: April 18, 2023Inventors: Laura Gualandi, Sarah Wulhfard, Francesca Pretto, Catherine Pemberton-Ross, Alessandra Villa, Roberto De Luca
-
Patent number: 11613764Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.Type: GrantFiled: July 15, 2019Date of Patent: March 28, 2023Assignee: MiNK Therapeutics, Inc.Inventors: Marc van Dijk, Volker Seibert, Cornelia Anne Mundt, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf, Daniel Leventhal, Sébastien Lalevée, Reed Masakayan
-
Patent number: 11603409Abstract: The present invention relates to a humanized DR4 antibody gene having apoptosis-inducing activity, and a dual-acting chimeric antigen receptor T cell or natural killer cell therapeutic agent, a secretory DR4 scFv antibody recombinant protein synthesized by using a humanized DR4 scFv antibody gene (humanized anti-DR4 scFv) may be used as an anticancer drug specifically targeting DR4 by binding to DR4 expressed on surface of the cancer cells to induce apoptosis of the cancer cells. In addition, the chimeric antigen receptor (CAR) using the humanized DR4 scFv antibody gene is predicted to have a strong anticancer immune effect as a dual-acting cell therapeutic agent, which is capable of simultaneously inducing apoptosis in cancer cells by DR4 and exhibiting a cytotoxic effect for cytotoxic T lymphocytes or natural killer cells by binding to DR4 expressed on the surface of cancer cells, as a DR4-specific CAR-T cell or CAR-NK cell therapeutic agent.Type: GrantFiled: June 5, 2018Date of Patent: March 14, 2023Assignee: GENEUIN-TECH CO., LTD.Inventor: Hyun Joo Youn
-
Patent number: 11578127Abstract: The present invention provides novel full-length human antibodies that bind to human Fc epsilon-R1 alpha (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both Fc epsilon-R1 alpha and CD3 and activate T cells via the CD3 complex in the presence of Fc epsilon-R1 alpha-expressing cells. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced Fc epsilon-R1 alpha-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of allergies, including anaphylaxis.Type: GrantFiled: August 22, 2019Date of Patent: February 14, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Jamie M. Orengo, Andre Limnander, Jee H. Kim, Andrew J. Murphy
-
Patent number: 11566072Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.Type: GrantFiled: August 8, 2018Date of Patent: January 31, 2023Assignees: Orionis Biosciences, Inc., Orionis Biosciences BVInventors: Nikolai Kley, Jan Tavernier, Lennart Zabeau, Erik Depla
-
Patent number: 11534461Abstract: The present disclosure provides binding proteins and TCRs with high affinity and specificity against Merkel cell polyomavirus T antigen epitopes or peptides, T cells expressing such high affinity Merkel cell polyomavirus T antigen specific TCRs, nucleic acids encoding the same, and compositions for use in treating Merkel cell carcinoma.Type: GrantFiled: November 14, 2017Date of Patent: December 27, 2022Assignees: FRED HUTCHINSON CANCER CENTER, UNIVERSITY OF WASHINGTONInventors: Aude G. Chapuis, Paul T. Nghiem, Megan S. McAfee, Natalie J. Miller, Kelly Garneski Paulson, David Martin Koelle, Thomas M. Schmitt, Candice Church
-
Patent number: 11524988Abstract: Disclosed herein are methods of producing chimeric antigen receptor (CAR) T cells using substrates, such as artificial antigen presenting cells, containing on a surface a a heparin binding domain (HBD), anti-CD3 single chain antibodies, anti-CD28 single chain antibodies (scFv), and optionally anti-41BBL antibodies. Anti-CD3 and Anti-CD28 scFvs bind and activate expanding T cells ex vivo, while the Heparin Binding Domain binds the viral vector, thereby bringing the T cells into close proximity with virus for effective gene transfer. This is a less costly, renewable, modifiable, and efficacious alternative to coated beads and RetroNectin® for gene transfer.Type: GrantFiled: September 19, 2017Date of Patent: December 13, 2022Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventor: Marco Davila
-
Patent number: 11525004Abstract: Disclosed are compositions and methods for targeted treatment of CD123-expressing cancers. In particular, recombinant antibodies are disclosed that are able to engage T-cells to destroy CD123-expressing malignant cells.Type: GrantFiled: July 18, 2018Date of Patent: December 13, 2022Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventor: Marco L. Davila
-
Patent number: 11517590Abstract: In order to improve the efficiency of gene introduction in CAR therapy employing a transposon method, provided is a method for preparing genetically-modified T cells expressing chimeric antigen receptor, comprising: (1) a step of preparing non-proliferative cells which are obtained by stimulating a group of cells comprising T cells using an anti-CD3 antibody and an anti-CD28 antibody followed by a treatment for causing the cells to lose their proliferation capability; (2) a step of obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene has been introduced using a transposon method; (3) a step of mixing the non-proliferative cells prepared by step (1) with the genetically-modified T cells obtained by step (2), and co-culturing the mixed cells while stimulating the mixed cells using an anti-CD3 antibody and anti-CD28 antibody; and (4) a step of collecting the cells after culture.Type: GrantFiled: October 7, 2016Date of Patent: December 6, 2022Assignee: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEMInventors: Nobuhiro Nishio, Yozo Nakazawa, Miyuki Tanaka, Daisuke Morita, Yoshiyuki Takahashi
-
Patent number: 11512288Abstract: Provided herein are methods of activating immune cells. The method includes providing a population of immune cells and contacting the population of immune cells with a first agent and a second agent. The first agent includes an immune cell activator attached to a first binder moiety, and the second agent includes at least one capture oligomer. The at least one capture oligomer is capable of associating with the first binder moiety. Also provided are kits for activating immune cells.Type: GrantFiled: August 24, 2017Date of Patent: November 29, 2022Assignee: GLOBAL LIFE SCIENCES SOLUTIONS USA LLCInventors: Ernest William Kovacs, Anup Sood, Reginald Donovan Smith, Evelina Roxana Loghin, Padmaparna Chaudhuri, Vandana Keskar, Chrystal Mae Chadwick, Martin James Brown
-
Patent number: 11497768Abstract: CAR-T cells for cancer therapy are provided with an antibody that recognizes the MAGE-A4-derived-peptide/HLA-A2 complex. The antibody includes the VH amino acid sequence of SEQ ID NO: 36 and the VL amino acid sequence of SEQ ID NO: 38. The antibody preferably is provided with the amino acid sequence of SEQ ID NO: 32. Such CAR-T cells can be used in CAR infusion therapy in which a cancer-specific intracellular antigen is used.Type: GrantFiled: June 5, 2018Date of Patent: November 15, 2022Assignee: MIE UNIVERSITYInventors: Hiroshi Shiku, Yasushi Akahori, Yuya Kato, Yoshihiro Miyahara
-
Patent number: 11466070Abstract: The present invention provides a chimeric antigen receptor (CAR) system comprising; (i) a receptor component comprising a antigen binding domain and a first binding domain; and (ii) a signalling component comprising a signalling domain and a second binding domain which binds the single domain binder of the first binding domain of the receptor component wherein either the first or second binding domains comprise a single domain binder, and wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent, the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain; whereas in the presence of the agent, the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain.Type: GrantFiled: February 10, 2017Date of Patent: October 11, 2022Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Shaun Cordoba, Simon Thomas, Shimobi Onuoha, Maria Stavrou
-
Patent number: 11459543Abstract: The invention provides a recombinant chimeric antigen receptor (CAR) gene, a vector containing the same, a CAR-T cell and a use thereof. The recombinant CAR gene comprises a nucleic acid sequence encoding an antigen-binding portion of a CD30 antibody, a transmembrane portion and a CD137 cytoplasmic functional region and a CD3zeta cytoplasmic functional region linked in any order; also provides a method of treating Hodgkin's lymphoma or anaplastic large cell lymphoma or other CD30-positive tumors using the CAR-T cells of the invention.Type: GrantFiled: November 16, 2018Date of Patent: October 4, 2022Assignee: YIMING (BEIJING) CELL BIOTECH LTD.Inventor: Xiulian Sun
-
Patent number: 11434291Abstract: Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; determining that the non-diabetic subject (1) is substantially free of antibodies against zinc transporter 8 (ZnT8), (2) is HLA-DR4+, and/or (3) is not HLA-DR3+; and administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject.Type: GrantFiled: May 14, 2020Date of Patent: September 6, 2022Assignee: Provention Bio, Inc.Inventors: Francisco Leon, Kevan C. Herold, Jay S. Skyler
-
Patent number: 11407839Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.Type: GrantFiled: March 11, 2019Date of Patent: August 9, 2022Assignee: Ichnos Sciences SAInventors: Antoine Attinger, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
-
Patent number: 11400145Abstract: The present invention relates generally to a population of stem cells (e.g., iPSCs or HSCs) that comprise nucleic acids encoding a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, for example two distinct tumour antigenic determinants. The present invention is also directed to a population of T cells that co-express a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, such as two distinct tumour antigenic determinants. The cells of the present invention can be derived from chosen donors whose HLA type is compatible with significant sectors of the populations, and are useful in a wide variety of applications, in particular in the context of the therapeutic treatment of neoplastic conditions.Type: GrantFiled: November 23, 2016Date of Patent: August 2, 2022Assignee: CARTHERICS PTY. LTD.Inventors: Richard Boyd, Alan Trounson, Hiroshi Kawamoto, Peter John Hudson, Runzhe Shu
-
Patent number: 11292838Abstract: The invention relates to a method for generating an antibody binding to a cell surface protein of interest, the method comprising the following steps: (a) providing a non-human cell which does not express the endogenous form of the cell surface protein of interest but expresses an exogenous form of the cell surface protein of interest comprising at least one human segment; (b) immunization of a non-human animal with the cell line provided in step (a); (c) generation of hybridomas from the immunized non-human animal of step (b); (d) screening for an antibody that binds to the cell surface protein of interest by contacting the antibodies secreted by the hybridomas of step (c) with human cells which do not express the endogenous form of the cell surface protein of interest but express an exogenous form of the cell surface protein of interest comprising at least one human segment.Type: GrantFiled: June 1, 2016Date of Patent: April 5, 2022Assignee: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Dolores Schendel, Slavoljub Milosevic, Tanja Herrmann, Michaela Kügler
-
Patent number: 11293009Abstract: In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.Type: GrantFiled: January 5, 2021Date of Patent: April 5, 2022Assignee: Iovance Biotherapeutics, Inc.Inventors: Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
-
Patent number: 11267864Abstract: The present invention relates to an isolated T cell receptor (TCR) specific for NY-ESO-1/LAGE-1 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.Type: GrantFiled: January 28, 2019Date of Patent: March 8, 2022Assignee: Medigene Immunotherapies GmbHInventors: Carina Wehner, Manon Weis
-
Patent number: 11254726Abstract: Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.Type: GrantFiled: April 14, 2021Date of Patent: February 22, 2022Assignee: A2 Biotherapeutics, Inc.Inventors: Carl Alexander Kamb, Agnes E. Hamburger, Breanna Diandreth, Mark E. Daris, Kiran Deshmukh